Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 258Carcinoma, Non-Small-Cell Lung 226Carcinoma, Renal Cell 143Neoplasm Metastasis 97Neoplasms 93Carcinoma, Hepatocellular 85Squamous Cell Carcinoma of Head and Neck 84Colorectal Neoplasms 81Lung Neoplasms 73Stomach Neoplasms 56Pancreatic Neoplasms 56Carcinoma, Transitional Cell 49Hodgkin Disease 47Urinary Bladder Neoplasms 42Breast Neoplasms 40Ovarian Neoplasms 37Head and Neck Neoplasms 37Triple Negative Breast Neoplasms 34Small Cell Lung Carcinoma 33Sarcoma 32Prostatic Neoplasms 32Glioblastoma 32Brain Neoplasms 32Recurrence 27Kidney Neoplasms 27Multiple Myeloma 25Uveal Melanoma 23Esophageal Neoplasms 23Uterine Cervical Neoplasms 22Skin Neoplasms 22

Interventions

Amifostine 19Cisplatin 15Radiotherapy 13Etoposide 10Cyclophosphamide 9Carboplatin 8Paclitaxel 7Filgrastim 7Drug Therapy 5Cytarabine 5apatinib 4sodium thiosulfate 3Methylprednisolone 3Methotrexate 3Gemcitabine 3Docetaxel 3sargramostim 2pegfilgrastim 2etoposide phosphate 2camrelizumab 2Vincristine 2Pyridoxine 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Mitoxantrone 2Melphalan 2Irinotecan 2Ifosfamide 2Fibroblast Growth Factor 7 2Epoetin Alfa 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Drug-Related Side Effects and Adverse Reactions × Nivolumab × Clear all
NCT05652673 2025-02-28

Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial

Erasmus Medical Center

Phase NA Recruiting
80 enrolled
Dermatologic

Melanoma, Drug-Related Side Effects and Adverse Reactions

NCT03638375 2023-12-12

ACTME

Leiden University Medical Center

Phase 1/2 Unknown
34 enrolled
Dermatologic

Melanoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡